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Lymphatic filariasis and onchocerciasis are severe
diseases caused by filarial worms and affect more
than 150 million people worldwide. Endosymbiotic
a-proteobacteria Wolbachia are essential for these
parasites throughout their life cycle. Using a high-
throughput chemical screen, we identified a benz-
imidazole compound, wALADin1, that selectively
targets the d-aminolevulinic acid dehydratase
(ALAD) of Wolbachia (wALAD) and exhibits macrofi-
laricidal effects on Wolbachia-containing filarial
worms in vitro. wALADin1 is a mixed competitive/
noncompetitive inhibitor that interferes with the
Mg2+-induced activation of wALAD. This mechanism
inherently excludes activity against the Zn2+-depen-
dent human ortholog and might be translatable to
Mg2+-responsive orthologs of other bacterial or
protozoan pathogens. The specificity profile of
wALADin1 derivatives reveals chemical features
responsible for inhibitory potency and species selec-
tivity. Our findings validate wALADins as a basis for
developing potent leads that meet current require-
ments for antifilarial drugs.
INTRODUCTION
Lymphatic filariasis and onchocerciasis are vector-borne
diseases caused by the filarial nematodesWuchereria bancrofti,
Brugia timori, Brugia malayi, and Onchocerca volvulus and are
rated asmajor public health problems by theWorld Health Orga-
nization. More than 1.2 billion inhabitants in endemic countries
are at risk of developing the disabling and stigmatizing chronic
diseases, i.e., lymphedema and hydrocele in lymphatic filariasis,
or severe dermatitis and blindness in onchocerciasis (Hoerauf
et al., 2011; Taylor et al., 2010).
Mass drug administration programs (MDA) using annual treat-
ment with a combination therapy of diethylcarbamazine (DEC) or
ivermectin (IVM) plus albendazole are used in many endemic
countries (Global programme to eliminate lymphatic filariasis,Chemistry & Biology 20, 1772009, 2011) to reduce the transmission of filarial disease, mainly
by killing offspring microfilariae (MF), and to prevent exacerba-
tion of the disease (Hoerauf et al., 2011; Taylor et al., 2010), while
adult worms that persist in the human host for several years are
merely paralyzed.
In an environment with increasing reports of suboptimal
responses against standard IVM and DEC therapy (Bourguinat
et al., 2011; Churcher et al., 2009; Esterre et al., 2001; Osei-
Atweneboana et al., 2011) and the exclusion of use of either
drug in certain geographical regions due to adverse effects of
DEC in onchocerciasis and IVM in loiasis (Gardon et al., 1997),
the call for novel antifilarial drugs or treatment options has
been raised (Bockarie and Deb, 2010).
As a step toward novel antifilarial pharmacotherapy, the spot-
light has turned on endosymbiotic a-proteobacteria, known as
Wolbachia, that are found in all filarial species causing lymphatic
filariasis or onchocerciasis (Taylor et al., 2005). Depletion of
prokaryotic Wolbachia from its hosts by tetracycline antibiotics
leads to sterility of adult worms followed by their death, showing
that Wolbachia are a target for antifilarial drug design (Hoerauf
et al., 2000). However, despite the efficacy of doxycycline with
regard to the sterilization of worms, alleviation of pathology,
and successful clinical use (Hoerauf et al., 2009), the logistically
complicated and expensive treatment regimens and contraindi-
cations for large groups in the population prevent its use in MDA
(Geary and Mackenzie, 2011; Hoerauf et al., 2009).
In the annotated genome from theWolbachia endosymbiont of
B. malayi, several essential biochemical pathways such as
purine, riboflavin, and heme biosynthesis were identified that
are absent or incomplete in the filarial host (Foster et al., 2005;
Ghedin et al., 2007) and are considered promising sources of
novel targets in antifilarial drug development (Slatko et al.,
2010; Wu et al., 2009). A candidate target inWolbachia is d-ami-
nolevulinic acid dehydratase (wALAD; also known as porphobili-
nogen [PBG] synthase, E.C. 4.2.1.24, encoded by the hemB
gene), an enzyme that catalyzes the first common step of tetra-
pyrrole synthesis—namely, the condensation of two molecules
of 5-aminolevulinic acid (5-ALA) to PBG, a function conserved
in all organisms that endogenously synthesize heme, chloro-
phyll, or corrins (Jaffe, 2004).
To explore wALAD as a target for antifilarial therapy, we de-
signed a wALAD activity-based chemical screening assay to–187, February 21, 2013 ª2013 Elsevier Ltd All rights reserved 177
Figure 1. HTS Identifies the Substituted Benzimidazole wALADin1 as a Species-Specific Inhibitor of wALAD
Recombinant wALAD was subjected to HTS (Z0 = 0.65 ± 0.20) against a library of 18,000 small molecules.
(A) One primary screening plate on which the most potent species-selective inhibitor, called wALADin1 (arrow), was detected. Positive control (Pos. Ctrl.) of the
enzymatic assay contained protein, substrate, and 6.7% DMSO; for negative control (Neg. Ctrl.), substrate was omitted.
(B) Chemical structure of wALADin1.
(C) Dose-response curve for wALADin1 incubated with wALAD and hALAD revealing species-selective inhibition wALAD (IC50,11 mM at pH 8.0). hALAD is only
marginally affected (IC50 > 500 mM for pH 7.5; IC50 > 1 mM for pH 8.0). The graph is representative of three experiments showing mean ± SD.
(D) Melting curve of 5 mM wALAD measured as an increase in fluorescence intensity of the environmentally sensitive dye SYPRO Orange; increasing concen-
trations of wALADin1 stabilized wALAD tertiary structure (rightward shift of the melting curves).
See also Figure S1 and Table S1.
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wALADin1, a Filaricidal Wolbachia ALAD Antagonistidentify wALAD inhibitors from a library of 18,000 drug-like
compounds. Here, we report the discovery of a class of
substituted benzimidazole-5-carboxylic acid structures, called
wALADins, as species-selective inhibitors of wALAD that
show only negligible inhibition of the human ortholog. We
demonstrate macrofilaricidal effects of wALADin1 in Wolba-
chia-containing filarial worms in an ex vivo culture system,
a finding that will allow the exploitation of this exciting class of
wALAD inhibitors for the future development of potent antifilarial
leads for drugs that might eradicate lymphatic filariasis and
onchocerciasis.
RESULTS
Identification of a Specific wALAD Inhibitor
We established a high-throughput screening (HTS)-compatible
assay by monitoring the wALAD-catalyzed conversion of 5-
ALA to PBG, the formation of which was detected by a colored
condensation product with p-dimethylamino-benzaldehyde
(Ehrlich’s Reagent) at 555 nm (see a detailed overview of the
HTS assay in Table S1 available online). A chemical library
containing 18,000 diversity-based drug-like small molecules
(Hafner et al., 2006, 2008; Niebel et al., 2010; Yamazaki et al.,
2007) was screened to identify inhibitors of wALAD. The average
assay quality parameter Z0 was 0.65 ± 0.20 throughout the
screening, indicating robust assay performance (Figure 1A).178 Chemistry & Biology 20, 177–187, February 21, 2013 ª2013 ElseThe screening revealed a cluster of substituted benzimidazole
derivatives that inhibited wALAD activity in a dose-dependent
manner, while activity of the human ortholog hALAD was only
marginally affected. The most potent of these compounds was
termed wALADin1 1 (wolbachia ALAD inhibitor 1) (Figure 1B). It
inhibited wALAD with a half maximal inhibitory concentration
(IC50) of 11 mM compared to an extrapolated IC50 of
740 mM for hALAD (Figure 1C). hALAD remained unaffected
by wALADin1 both at pH 8, the pH optimum of wALAD, and at
pH 7.5, which is within the hALAD optimal pH range. The >60-
fold discrimination in inhibitory potency of the endobacterial
over the human ALAD ortholog indicates that wALADin1 is
a species-selective inhibitor.
We next performed thermal shift assays to demonstrate that
wALADin1 binds towALAD. As hydrophobic side chains become
exposed upon thermal denaturation, the melting curve of
a protein can be measured as an increase in fluorescence inten-
sity of the environmentally sensitive fluorescent dye Sypro
Orange (Zhang and Monsma, 2010). Increasing concentrations
of wALADin1 in the low micromolar range led to a concentra-
tion-dependent rightward shift of the melting curve consistent
with stabilization of the protein by ligand binding under enzy-
matic assay buffer conditions (Figure 1D). For hALAD, only
concentrations of wALADin1 R250 mM led to a slight shift of
the melting temperature, but DTm values did not exceed 1.5
C
at 1 mM (Figure S1A). wALADin1 did not interact with othervier Ltd All rights reserved
Figure 2. wALADin1 Functionally Competes with Enzymatic Activation by Mg2+ and Acts by Mixed Competitive, Noncompetitive Inhibition
(A) wALAD activity is Mg2+ responsive (EC50 = 11 mM; near-saturating 5-ALA concentration of 1 mM). Graph depicts mean ± SEM of three experiments.
(B) Mg-response curve of wALAD (non-saturating 5-ALA concentration of 200 mM) is shifted to the right by increasing concentrations of wALADin1
(C) 5-ALA serial dilutions in the presence of different concentrations of wALADin1. Lines were fitted to a double hyperbole (Prism 5.0) accounting for different
oligomeric structures with different activities (R2 = 0.99902–0.9961).
(D) Linearized Eadie-Hofstee representation revealing reduced Vmax and increased KM upon inhibition with wALADin1.
(B), (C), and (D) show means ± SD of two experiments.
See also Figure S2.
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(Figures S1B and S1C). These experiments demonstrate that
wALADin1 specifically binds to wALAD.
wALADin1 Interferes with wALAD Activation by Mg2+
Having qualitatively described the binding between wALADin1
and its enzymatic target, we characterized this inhibitor in terms
of its molecular mode of action. As wALAD is a Mg2+-responsive
enzyme (EC50, 11 mM, Figure 2A), we studied the influence of
Mg2+ concentration on the inhibitory properties of wALADin1.
The observed rightward shift of the Mg2+ response curve in the
presence of increasing concentrations of wALADin1 indicates
a functional competition between inhibition by wALADin1 and
the activation induced by Mg2+ (Figure 2B).
We then determined the underlying type of inhibition by
measuring enzymatic activity at different wALADin1 concentra-
tions with varying concentrations of the 5-ALA substrate. d-ami-
nolevulinic acid dehydratase (ALAD) proteins are morpheeins
that can form multiple homomeric assemblies that show
dramatic differences in their catalytic activities (Jaffe, 2005; Law-
rence et al., 2008). Nonlinear regression analysis (NLR) assuming
a double hyperbolic progression representing different Vmax andChemistry & Biology 20, 177KM values of different oligomeric assemblies of the morpheein
(with high affinity and activity for an octameric and reduced
affinity for lower molecular weight assemblies) gave the best
fits (R2 values, 0.9902–0.9961). An increase in both apparent
KM values and a reduction in the overall Vmax in the presence
of increasing 5-ALA concentrations was observed (at 6.7%
dimethyl sulfoxide [DMSO]: Vmax1 = 0.071, KM1 = 163 mM,
Vmax2 = 0.014, and KM2 = 3.4 mM; at 25 mM wALADin1:
Vmax1 = 0.046, KM1 = 456 mM, Vmax2 = 0.023, and KM2 =
6.4 mM). For 100 mM wALADin1, a double hyperbolic fit was
not superior to a simple hyperbole (Vmax = 0.049, KM =
1.6 mM). The inhibitory mechanism predicted by NLR data is
consistent with the linearized Eadie-Hofstee representation sug-
gesting a mixed competitive/noncompetitive mode of inhibition
(Figures 2C and 2D). NLR assuming classic mixed model inhibi-
tion had a slightly poorer fit but was useful for approximation of
the inhibition constant Ki of 5.95 ± 0.95 mM (a = 31.44 ± 9.59;
R2 = 0.9794) at 1.0 mM MgCl2.
For pea and human ALAD compounds that stabilize the inac-
tive hexameric over the active octameric, conformation elicited
ortholog-specific inhibition. Native PAGE analysis of wALAD,
with hALAD used as controls for the localization of hexameric–187, February 21, 2013 ª2013 Elsevier Ltd All rights reserved 179
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wALADin1, a Filaricidal Wolbachia ALAD Antagonistand octameric bands (Figure S2A), revealed that preincubation
with wALADin1 did not alter the oligomeric equilibrium but it
bound to and reduced activity of wALAD octamers in an in-gel
activity assay (Figure S2B).
wALADin1 Elicits Filaricidal Activity in Worms
Containing Wolbachia
Having characterized the inhibitory effects of wALADin1 on
wALAD at the molecular level, we proceeded to demonstrate
its antifilarial activity. We therefore tested wALADin1 against
the rodent filarial nematode Litomosoides sigmodontis (Ls),
a model for human filarial nematodes causing lymphatic filariasis
and onchocerciasis that also harbors Wolbachia endobacteria
(Hoerauf et al., 1999). wALADin1 was tested against Ls in a
coculture assay with monkey kidney LLC-MK2 feeder cells
within a concentration range between 125 and 500 mM. These
levels exceeded the IC50 concentration of the enzymatic
assay by 10-fold to 50-fold—an excess we expected to be
required to achieve near-complete inhibition in the living
worm. Indeed, we observed a concentration- and time-depen-
dent decrease in motility of adult Ls females for all concen-
trations tested in the course of the 17-day culture period
(Figure 3B).
Healthy worms make very quick, fidgeting continuous
movements over their entire body length. The phenotype of
wALADin1-treated worms had a specific and characteristic
appearance: the worms first formed slowly moving ball- or
knot-like shapes (rated with a motility score of 4) that later
became largely immotile (score of 3). This phenotype preceded
the stretched low-motility forms that characterized the pheno-
type of dying worms (Figure 3A; Movies S1, S2, S3, S4, and
S5). The pronounced filaricidal effect of wALADin1 was consis-
tent for all concentrations tested as quantified in a viability
measurement (MTT assay; Mann-Whitney U test, p < 0.05) (Fig-
ure 3C). Median viability was reduced to 44%, 27%, or 7.5%
(normalized to 1% DMSO groups as 100% viability and dead
control group set to 0%) by 125 mM, 250 mM, or 500 mM, respec-
tively, suggesting an IC50 concentration of100 mM in this assay.
We complemented these studies with cytotoxicity experi-
ments using wALADin1 on both LLC-MK2 (monkey kidney) cells
and human embryonic kidney (HEK) cells. Viability of the cells
was measured by MTT assay after 48 hr incubation at different
concentrations of wALADin1. Viability was reduced for both
cell lines at 500 mM and 1 mMwALADin1 (Figure S3A). However,
at 500 mM. the LLC-MK2 cell lawn in the worm coculture was
always intact, and cells showed no sign of apoptosis. Thus,
the observed effect on viability at that concentration may be
attributed to an antiproliferative activity of wALADin1 rather
than cytotoxicity.
To dissect the contributions of nonspecific cytotoxic and
specific antifilarial effects resulting from ALAD inhibition in the
Wolbachia endosymbionts of Ls worms, we tested wALADin1
against A. viteae (Av), another model rodent filarial nematode
that does not have Wolbachia (Hoerauf et al., 1999). We per-
formed a nucleotide query of the recently completed Av genome
database (Blaxter, 2012) using the hemB genes (that code
for ALAD) of Wolbachia of B. malayi, human, and yeast as
input sequences (accession number AE017321.1, gene locus
Wbm0373; X64467; J03493) that showed that there are no180 Chemistry & Biology 20, 177–187, February 21, 2013 ª2013 Elseorthologous genes in this worm. Therefore Av should only be
sensitive to nonspecific cytotoxic effects of the compounds.
Exposure to 500 mM wALADin1 had an effect, reducing Av
motility to a score of 4 within 2 hr, and motility remained at this
level for10 days (Figure 3D). However, there was no significant
influence on the viability of Av worms in the more accurate MTT
assay (Figure 3E). Note that direct comparison of motility scores
between Ls and Av is restricted by their different motility pheno-
types (Avwormsmovemore slowly) (Supplemental Experimental
Procedures; Movies S1, S2, S3, S4, and S5). The characteristic
balled phenotype observed in wALADin1-treated Ls was absent
in Av. At wALADin1-concentrations lower than 500 mM, neither
an effect on viability nor one on motility of Av was detectable,
whereas a >50% impairment of viability on Ls was seen already
at 125 mM. Taken together, the antifilarial effect of wALADin1 on
Ls is thus due to the dependence of this species on Wolbachia.
The antifilarial effect of wALADin1 might be enhanced by
a combination of reduced heme levels and excess 5-ALA-
induced toxicity, as 5-ALA levels are expected to build up as
a consequence of ALAD inhibition. In order to verify this
hypothesis, motility and viability of Ls as a function of 5-ALA
concentration were assessed. Both parameters were reduced
upon treatment with 1 or 5 mM 5-ALA (Figures S4A and
S4B). Thus, exposure to increased 5-ALA levels indeed has a
filaricidal effect.
Specificity of wALAD Inhibitors
The antifilarial activity and the species selectivity of wALAD inhi-
bition encouraged us to characterize in greater depth the activity
and specificity of wALADin1 1 (all compounds are continuously
numbered and are referred to as bold numbers 1–16). We first
assessed the general influence of single substituent groups R1,
R2, and R3 present in the benzimidazole scaffold of 1 on the over-
all inhibitory activity by successively replacing each group with
a hydrogen atom (Compounds 2, 3, and 4) (Table 1). Compound
3 retained the inhibitory potency of wALADin1 indicating that the
2-[(2-thienylcarbonyl)amino]ethyl residue of 1 is dispensable for
inhibitory activity. In contrast, the absence of the R1 3-CF3 benzyl
group (2) or the R3-COOH function (4) led to an abrogation of
inhibitory activity. A methyl ester variant of 1, compound 5,
was equally inactive as 4, revealing the importance of the
carboxyl group for wALAD inhibition: either the solubility of the
compounds is affected in a way that prevents inhibitory potency,
or the carboxylic acid moiety is functionally required. To test this,
we performed a carboxylate scan by attaching the COOH-group
at benzimidazole atoms C6, C4, and C7 (6, 7, and 8, respectively).
While 7 was inactive, 6 and 8 showed a 29-fold and 15-fold loss
of inhibitory potency, respectively, indicating that activity is
affected by the positioning of the carboxy group rather than
solubility.
Isomers 6–8were also tested in the thermal shift assay for wA-
LAD binding. The noninhibitory compound 7 does not stabilize
wALAD at all, whereas 6 and 8 stabilize the protein with discern-
ible but smaller melting shifts (DTm) than wALADin1 (Figure S1),
which is commonly interpreted as reduced binding affinities
(Zhang and Monsma, 2010). These results concur with the IC50
values determined in the enzymatic inhibition data. Different
entropic and enthalpic contributions to the free energy of binding
between 6 and 8 may explain the considerably larger DTm of 6,vier Ltd All rights reserved
Figure 3. wALADin1 Has a Wolbachia-Dependent Macrofilaricidal Activity In Vitro
(A) Pictures of female Ls adult worms showing different phenotypes seen in the course of wALADin1 treatment.
(B–E) Survival assays with theWolbachia-containing filaria Ls in (B) and (C) and theWolbachia-devoid control filaria Av in (D) and (E) with wALADin1. Worms were
cultivated until single 1% DMSO-treated control worms began to lose motility (14–17 days). (B) Motility of Ls and (D) Av worms treated with wALADin1 or 1%
DMSOwere rated visually as described in the Supplemental Experimental Procedures. Motility graphs showmedian values (n = 6). Worm viability was measured
byMTT assay at the end of treatment for Ls (C) and Av (E). Optical density (OD) data were normalized to the 1%DMSO control (100% viability), and dead (frozen +
boiled) worms were used as negative control. Data are representative of two experiments. Significance was tested by nonparametric two-tailed Mann-Whitney U
test; significant p values are depicted in the graph. For Av, data of two independent experiments are shownmarked with superscript I and II in (D); for normalized
viability data, control worms from both experiments were pooled in (E). d, days.
See also Figures S3 and S4 and Movies S1, S2, S3, S4, and S5.
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wALADin1, a Filaricidal Wolbachia ALAD Antagonistbeing the slightly less potent inhibitor. Overall, these results
demonstrate that the position of the carboxylic acid at the benz-
imidazole ring is crucial for the inhibitory potency and indicate an
involvement of this group in binding, e.g., by salt bridge
formation.
Alterations of the R1-substituent generally led to a decrease in
inhibitory activity. For example, moving the CF3 group in the R
1-Chemistry & Biology 20, 177isomer of wALADin1 from position 3 (1) to position 4 (9) resulted
in a 4-fold reduced activity. As R2 is apparently dispensable for
inhibition, we synthesized a series of R1-variants with an R2-H
substituent. Interestingly, compound 10, the R2-H derivative of
compound 9 was 2-fold less active (IC50 88 mM) than 9, indi-
cating R2-substituents may confer additional potency. Com-
pared to 3, the re-positioning of the CF3 residue in R
1 (10) or–187, February 21, 2013 ª2013 Elsevier Ltd All rights reserved 181
Table 1. IC50 Values Obtained for the Inhibition of wALAD and hALAD by wALADin1 and Derivatives under Standard Conditions
Compound R1 Residue R2 Residue R3 Residue
R3 Position at
Benzimidazole
Wolbachia ALAD Human ALAD
IC50 (mM) R
2 IC50 (mM) R
2
1 3-trifluoromethyl benzyl 2-[(2-thienylcarbonyl)amino]ethyl COOH C5 11.1 ± 1.0 0.9517 739 ± 103 0.8582
2 H 2-[(2-thienylcarbonyl)amino]ethyl COOH C5 * – * –
3 3-trifluoromethyl benzyl H COOH C5 13.0 ± 1.2 0.9638 197 ± 20 0.9457
4 3-trifluoromethyl benzyl 2-[(2-thienylcarbonyl)amino]ethyl H C5 * – * –
5 3-trifluoromethyl benzyl 2-[(2-thienylcarbonyl)amino]ethyl COOCH3 C5 * – * –
6 3-trifluoromethyl benzyl 2-[(2-thienylcarbonyl)amino]ethyl COOH C6 317 ± 53 0.9022 * –
7 3-trifluoromethyl benzyl 2-[(2-thienylcarbonyl)amino]ethyl COOH C4 * – * –
8 3-trifluoromethyl benzyl 2-[(2-thienylcarbonyl)amino]ethyl COOH C7 164 ± 14 0.9551 * –
9 4-trifluoromethyl benzyl 2-[(2-thienylcarbonyl)amino]ethyl COOH C5 38.6 ± 6.2 0.9670 618 ± 105 0.9186
10 4-trifluoromethyl benzyl H COOH C5 87.7 ± 10.5 0.9487 173 ± 12 0.9730
11 2-trifluoromethyl benzyl H COOH C5 293 ± 67 0.8503 145 ± 7.2 0.9854
12 benzyl H COOH C5 197 ± 33 0.9042 213 ± 6.3 0.9934
13 3-methyl benzyl H COOH C5 134 ± 17 0.9394 222 ± 11 0.9864
14 3-methyl benzyl H COOH C5 205 ± 12 0.9922 156 ± 7.8 0.9881
15 CH3 H COOH C5 * – * –
16 H H COOH C5 * – 511 ± 36 0.9780
The results of two independent experiments were pooled for each compound. Compounds were tested in a 2-fold dilution row, with the highest
concentration tested being 533 mM.Where low inhibition (<50%)was observed at the highest concentration tested, extrapolated IC50 values are shown
in italics. Asterisks indicate the absence of inhibitory activity.
See also Figure S1.
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wALADin1, a Filaricidal Wolbachia ALAD Antagonistits change to CH3 (13) led to 8- and 10- fold reduced potency. As
further R1 substitutions also led to a significant reduction (11–14)
or abrogation of inhibitory activity (15, 16) we conclude that R1 in
general and its CF3 group in particular are important for inhibitory
potential so that the 3- CF3 benzyl residue is optimal among the
series of compounds tested.
It is intriguing that all compounds featuring the 2-[(2-thienyl-
carbonyl)amino]ethyl at R2 (1, 4–9) are, at best, only very weak
inhibitors of hALAD (R618 mM). In contrast, smaller R2-H
compounds (3, 10–14) have IC50 values between 145 and
222 mM for hALAD with compounds 11 and 14 being even
more potent inhibitors of the human than of the Wolbachia
protein. These data are summarized in Figure 4 and suggest
that, although the R2_substituent of wALADin1 is not required
for inhibiting wALAD, it is important for species selectivity, e.g.,
by imposing a steric hindrance for the hALAD binding site.
Despite the reduction in species selectivity, removal of the R2-
2-[(2-thienylcarbonyl)amino]ethyl group of the 473.5 Da mole-
cule wALADin1 resulting in 3 showed no loss of inhibitory activity
and presents the smaller 320 Da compound 3 as an improved
lead candidate.
In order to determine the antifilarial profile of wALADin1 deriv-
atives, selected compounds 3 (despite its reduced species
selectivity) and 6, neither of which was cytotoxic at 500 mM (Fig-
ure S3B), were tested for antifilarial activity against Ls (Figure 5)
in the ex vivo culture. Generally, the potent wALAD inhibitor 3
shows similar but slightly less potent antifilarial activity on Ls
compared to wALADin1, and it also induced the balled pheno-
type described earlier (Movies S1, S2, S3, S4, and S5). Motility
levels only became comparable to those induced by wALADin1
during the last days (scores 3 and 4 for 125 and 250 mM, respec-
tively). Viability was significantly reduced at 500 mM for 3 (38%182 Chemistry & Biology 20, 177–187, February 21, 2013 ª2013 Elsemedian residual viability), but the trend continued for the lower
doses.
The 500 mM compound 6, a less potent inhibitor that was still
able to bind to wALAD, showed less antifilarial potency than wA-
LADin1 but was stronger than 3, with Ls viability reduced to 24%.
The decreasemay be related to the rapid, non-ALAD/Wolbachia-
dependent activity seen in Av treated with 500 mM wALADin1
(Figure 3D). Taken together, the structural information of the
tested benzimidazole compounds and the pronounced antifilar-
ial activity in vitro observed for the twomost potent wALAD inhib-
itors (wALADin1 and 3) provides an excellent starting point for
the development of a more potent lead structure that targets
Wolbachia by the specific Mg2+-dependent mode of action we
have described herein.
DISCUSSION
Current antifilarial drug discovery strategies follow different
approaches: the worms may be targeted directly at nematode
proteins, e.g., involved in specific processes such as molting
(Gloeckner et al., 2010), or indirectly by killing their Wolbachia
endosymbionts. Whole-organism-screening approaches are
being carried out for both organisms to identify novel antifilarial
and anti-Wolbachia compounds and drug targets (Serbus
et al., 2012).Wolbachia-targeting drugs acting like classic antibi-
otics usually deplete the endobacteria from their hosts (Hoerauf
et al., 1999). In this study, we targeted a single biochemical
pathway considered essential for symbiosis and maintaining
worm homeostasis and that may therefore affect the worm
directly and more rapidly than Wolbachia-depleting drugs do.
The pathway we address is heme biosynthesis, and the target
enzyme is wALAD. As B. malayi worms only possess the genevier Ltd All rights reserved
Figure 4. Summary of Activity Data for wALAD Inhibition by wALADin Inhibitors
The R3-COOH residue is an explicit requirement for inhibitory function andmay be involved in salt-bridge formation in the binding site. R1 is important for inhibitory
activity, as all substitutions of the 3-CF3-methyl benzyl provoked, reduced, or annihilated inhibitory potency with a benzyl group as a minimum requirement. The
R2-2-[(2-thienylcarbonyl)amino]ethyl group of wALADin1 appears to be a major mediator of species selectivity. pos., position.
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wALADin1, a Filaricidal Wolbachia ALAD Antagonistfor ferrochelatase, the last enzyme of heme biosynthesis, and as
they are apparently unable to salvage heme from their environ-
ment in vitro, they are expected to depend on their endosymbi-
onts that possess the genes required for de novo heme biosyn-
thesis (Foster et al., 2005; Ghedin et al., 2007; Wu et al., 2009).
In contrast, the free-living nematodeCaenorhabditis elegans is
unable to synthesize heme de novo but relies on exogenous
heme sources it may exploit via a system of heme transporters
(Chen et al., 2012). It is interesting that non-Wolbachia carrying
filarial nematodes such as Av and L. loa, the genomes of which
have recently been sequenced (Broad Institute, 2012; Blaxter,
2012), are also heme auxotrophic and must acquire heme from
their environment, i.e., the mammalian host. However, it is not
known how these filariae actually cover their demand for
heme. It is assumed that Wolbachia once infected an ancestor
common to many filarial nematodes (McNulty et al., 2010) and
that Wolbachia-free filariae have lost the endosymbiont during
evolution. It is conceivable, albeit without experimental verifica-
tion, that these nematodes became independent of their endo-
symbionts by developing heme transport machineries that
allowed them to exploit exogenous heme sources.
Although it may not be completely ruled out that Wolbachia-
harboring filarial nematodes may be able to salvage heme from
their hosts at least during certain life stages (Attout et al.,
2005), the conservation of the heme biosynthetic pathway within
the extremely reduced Wolbachia genome (Foster et al., 2005)
highlights an evolutionary pressure for sustaining this pathway
(either for their own supply or for also provisioning to their hosts).
We have previously shown that, upon depletion of >99.8% of
Wolbachia from the rodent filarial nematode Ls by doxycycline,
the worms upregulated several mitochondrial encoded heme-
dependent subunits of the respiratory chain complexes hypoth-
esized to be a means to overcome the lack of heme supplied by
the endosymbiont (Stru¨bing et al., 2010). Treatment of B. malayi
adult worms with N-methyl mesoporphyrin, a specific ferroche-Chemistry & Biology 20, 177latase inhibitor, or succinyl acetone (4,6-dioxoheptanoic acid,
SA), a non-species-selective inhibitor of ALAD enzymes, led to
the death of the worms (Wu et al., 2009). Specificity of the effects
of SA is questionable since the high concentration used (3 mM)
also affected growth of heme-auxotrophic C. elegans. Further-
more, the substrate analog SA undergoes Schiff base formation
with a catalytic lysine residue (Erskine et al., 2001) also
conserved in the active center of the human ortholog (hALAD)
excluding its therapeutic use.
In a high-throughput chemical screen, we have identified
a class of specific, small molecule inhibitors, called wALADins,
that selectively target the Wolbachia ALAD ortholog and exhibit
antifilarial activity in vitro. Low mM inhibitory potency in the enzy-
matic assay and the corresponding high concentrations required
to achieve an antifilarial effect against worms in culture make
a successful use of these compounds in vivo a challenging but
worthy task. The present study paves the way for the develop-
ment of similar, but more potent, inhibitors (ideally with nanomo-
lar potency) as better drug candidates. These specific inhibitors
may further be applied as chemical biology tools to unravel the
role of Wolbachia-dependent heme biosynthesis in symbiosis
and to understand effects caused by depletion with antibiotics
(Stru¨bing et al., 2010).
In contrast to previously described ALAD inhibitors, wALADin1
neither acts as a competitive substrate analog nor stabilizes
inactive oligomeric assemblies like morphlock inhibitors (Law-
rence et al., 2008). wALADin benzimidazoles act by a mixed
competitive/noncompetitive mechanism that involves a func-
tional competition with Mg2+. The key to species selectivity lies
in the different metal cofactor usage of ALAD families and the
corresponding active site architecture and allosteric activation
mechanisms. wALAD lacks the cysteine-rich consensus se-
quence required for Zn2+ binding in the catalytic center that is
required for catalytic activity by all Zn2+-dependent orthologs
(Jaffe, 2003), including the human enzyme. Instead, wALAD is–187, February 21, 2013 ª2013 Elsevier Ltd All rights reserved 183
Figure 5. Antifilarial Activity of wAladin Derivatives 3 and 6 against Ls In Vitro
(A) Wolbachia-containing adult female Ls worms treated with 1% DMSO, 125–500 mM 3 or 500 mM 6. Median values are shown (n = 6).
(B)Worm viability measured byMTT assay at the end of treatment. Significancewas tested by nonparametric two-tailedMann-Whitney U test; significant p values
are depicted in the graph. DMSO and dead controls shown in this figure are from the same experiment as in Figure 3.
See also Figure S3 and Movies S1, S2, and S3.
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wALADin1, a Filaricidal Wolbachia ALAD Antagonistmore closely related to the plant (i.e., chloroplast) and several
other bacterial orthologs that use Mg2+ at the active and/or an
allosteric site (Frankenberg et al., 1999; Kervinen et al., 2000;
Wu et al., 2009). Despite sporadic evidence for a catalytic active
site Mg2+ ion substituting the function of the catalytic Zn2+ in Zn-
dependent orthologs (Kervinen et al., 2000; Petrovich et al.,
1996), no crystal structure includes such a Mg2+ ion. In contrast,
binding of the allosteric Mg2+ at a subunit-subunit interface
outside the active site is well documented by crystal structures,
and the ligand required for binding allosteric Mg2+ (Glu245 of
P. aeruginosa) is also conserved in the wALAD protein. Given
themonophasic nature of theMg2+ activation profile, we hypoth-
esize that the Mg2+ is associated with the well-described allo-
steric effect, although involvement of active site Mg2+ may not
be ruled out, given the high affinity binding of Mg2+ to theWolba-
chia ortholog (Kervinen et al., 2000; Shanmugam et al., 2010).
wALADin1 may act by competing with Mg2+ binding (at either
site), or it may bind to a different site and interfere with the allo-
steric activation process, i.e., allowing closure of the active site
lid upon binding of the second 5-ALA substrate to the active
site (Frankenberg et al., 1999; Jaffe, 2004). Determination of
the binding site of wALADin1 by X-ray crystallography will be
required to unravel the molecular mechanism of inhibition.
However, efforts to crystallize wALAD have not been successful.
Specific inhibition of wALAD by wALADin1 elicits a macrofilar-
icidal effect in the living worm in vitro with an IC50 of100 mM on
the Wolbachia-harboring Ls. In contrast, wALADin1 had little
effect on the Wolbachia-free Av. Thus, the antifilarial activity of
wALADin1 is Wolbachia dependent. Presumably, this effect
results from inhibiting endobacterial heme biosynthesis,
although additional targets in Wolbachia are possible. The
consistent, albeit weaker, antifilarial activity of 3, a similarly
potent wALAD inhibitor according to enzymatic inhibition exper-
iments, supports this conclusion. However, some findings indi-
cate an involvement of a secondary target of wALADins that
might act additively or in synergy to inhibit wALAD at high
concentrations: (1) the effect of wALADin1 on Av motility, (2)
cytotoxicity/growth suppression in cell culture above 500 mM,
and (3) loss of Ls motility and viability by 500 mM 6.184 Chemistry & Biology 20, 177–187, February 21, 2013 ª2013 ElseA potential secondary target may be filarial orthologs of the
human Kinesin-spindle protein (hKSP), a potential anticancer
drug target required for mitotic spindle assembly. Benzimidazole
chemotypes with a substitution pattern similar to that of the wA-
LADins but different in their substituent classes and activity
profiles target hKSP and inhibit cancer cell growth (Lahue
et al., 2009). The benzimidazole chemotype is also found in an-
thelminthic compounds like albendazole that target worm
b-tubulin (van den Enden, 2009). It has been shown recently
that the albendazole metabolite albendazole sulfone targets
Wolbachia and induces binary fission defects (Serbus et al.,
2012). An effect via this still unidentified benzimidazole target
is also possible for wALADins, and a detailed elucidation of the
Wolbachia and filarial phenotypes induced by these compounds
is required to unequivocally define the biological effector path-
ways. However, in light of an ongoing paradigm shift in drug
discovery away from single- to multitarget drugs (Hopkins,
2008; Schrattenholz and Soskic, 2008), we are now aiming at
the elucidation and exploitation of potential secondary targets
of wALADin1 in the development of more potent antifilarial
agents.
We have shown that the unique mechanism of ALAD inhibition
may already involve a second effector pathway: filarial worms
are susceptible to high concentrations of the wALAD substrate
5-ALA; these high concentrations are expected to accumulate
when ALAD is inhibited and may mediate pro-oxidative effects
and GABA agonism (Brennan and Cantrill, 1979; Warren et al.,
1998). GABA agonism itself can lead to a block of neuromuscular
activation of nematodes (Martin, 1985). In analogy to pathologic
conditions in humans and based on our results, it is possible that,
as a consequence to inhibition of wALAD, both 5-ALA toxicity
and heme deprivation may contribute in concert to the observed
macrofilaricidal effects. The 5-ALA-driven toxicity may even
result in an antifilarial effect, in case filarial worms are shown to
take up heme from its host under certain conditions. However,
the resulting concentrations and the distribution of 5-ALA in
Wolbachia and in the living worm remain to be determined.
ALAD has been explicitly proposed as a potential drug target
in the context of various infectious agents like Plasmodiumvier Ltd All rights reserved
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wALADin1, a Filaricidal Wolbachia ALAD Antagonistfalciparum (Dhanasekaran et al., 2004), Toxoplasma gondii
(Shanmugam et al., 2010), andPseudomonas aeruginosa (Frank-
enberg et al., 1999). The discovery of the ALAD-targeting antibi-
otic Alaremycin produced by Streptomyces (Awa et al., 2005)
shows that inhibiting ALAD is a method for antimicrobial killing
in nature. Lack of discriminatory power between microbial and
mammalian orthologs has been a major drawback for known
ALAD inhibitors that may now be overcome with species-selec-
tive wALADin benzimidazoles. These Mg2+-competitive inhibi-
torsmay be effective against a variety ofmicrobes and plants de-
pending onMg2+-responsive ALAD function andmay be used as
antibiotics, herbicides, or antiprotozoal agents.
SIGNIFICANCE
The filarial diseases lymphatic filariasis (lymphedema,
hydrocele, and elephantiasis) and onchocerciasis (severe
dermatitis and blindness) infect more than 150 million
people in developing countries, with 1.2 billion at risk of con-
tracting these diseases. While the distribution of antilarval
drugs such as ivermectin or diethylcarbamazine has been
used with success in many areas, mathematical modeling
has raised questions about the ability of these programs to
be efficacious in larger endemic regions. These programs
would require 5–20 years of biannual treatment to interrupt
transmission, with high costs and uncertain outcome. There
are increasing reports on the suboptimal response to iver-
mectin, the only drug available for onchocerciasis. There-
fore, a suitable replacement drug that is effective with
a shorter drug regime and that targets the adult worms
rather than larval stages is in urgent need. Here, we report
a significant step toward such a drug. We have subjected
the target d-aminolevulinic acid dehydratase (ALAD) of
Wolbachia, essential endobacteria of most filarial parasites
of humans, to HTS.We identified aWolbachia-specific inhib-
itor of ALADcalledwALADin1. wALADin1 inhibits via amixed
competitive and noncompetitive mechanism that alters the
induction of enzyme activity by Mg2+ and has biological
activity against the rodent filarial nematode Litomosoides
sigmodontis in vitro. By synthesizing derivatives of wALA-
Din1, we have identified key chemical motifs required for
this inhibitory activity and species selectivity. These com-
pounds are an excellent starting point for the development
of antifilarial leads that are urgently needed to achieve final
success of lymphatic filariasis and onchocerciasis elimina-
tion programs.
EXPERIMENTAL PROCEDURES
Reagents, Proteins, and Enzymatic Assay
The hemB gene (ALAD) sequence from wALAD and a cDNA-derived human
sequence had been previously cloned into the pET-21a vector (Wu et al.,
2009). His6-tagged proteins were expressedwithminor changes to the original
protocol as described in the Supplemental Experimental Procedures. Metal
ion dependencies of the proteins used in this study had been determined in
a previous study (Wu et al., 2009), in which specific protein activities had
been reported as 57.8 mmol PBG/mg of protein per hour for hALAD and
22.5 mmol PBG/mg of protein per hour for wALAD under optimal buffer condi-
tions. The high-throughput enzymatic screening assay is a simplified standard
assay for the detection of PBG with modified Ehrlich’s Reagent and is
described in detail in Table S1. IC50 determinations of inhibitors were per-Chemistry & Biology 20, 177formed manually using 500 nM wALAD in 100 mM Tris (pH 8.0) with 5 mM di-
thiothreitol (DTT), 1 mMMgCl2 or using 250 nM hALAD in 100 mM Tris (pH 7.5)
with 5 mM DTT, 10 mM ZnCl2. Ten micromolar of ZnCl2 is a standard concen-
tration used to assay Zn-dependent proteins at optimal activity (Lawrence
et al., 2008). Higher levels of Mg2+ are required to achieve optimal stimulation.
Physiological Mg2+ concentrations inside Wolbachia are unknown, but free
intracellular Mg2+ concentrations have been described in the range of 1–
10 mM for prokaryotic (Alatossava et al., 1985) and eukaryotic cells (Ebel
and Gu¨nther, 1980). Protein concentrations were adjusted so that substrate
turnover (at 200 mM 5-ALA) after 20 min of reaction at 36C was 7%–14%.
All reagents were purchased from Sigma, Carl Roth, PAA Laboratories, or
Life Technologies.
Thermal Shift Assay
Thermal melting curves of ALAD proteins were recorded on a Rotor-Gene RG-
3000 (Corbett Life Sciences) in the presence the fluorescent dye SYPRO
Orange, which elicits increased fluorescence intensities when bound to hydro-
phobic amino acids exposed during protein unfolding. Triplicate samples were
prepared of 5 mM (0.2 mg/ml) wALAD in 1 M Tris (pH 8.0), 5 mM DTT, 1 mM
MgCl2, different concentrations of wALADin1/derivatives or 1% DMSO as
control, and 163 SYPRO Orange in a final volume of 10 ml. Control proteins
were assayed under identical conditions at 8–163 SYPRO Orange, with
chicken egg white lysozyme measured at 3 mg/ml, BSA at 0.5 mg/ml, and
hALAD at 0.2 mg/ml in the presence of 10 mMZnCl2 instead ofMgCl2. Samples
were denatured with a heating rate of 0.5C/30 s from 27C to 95C. Fluores-
cence wasmeasured on the FAM (6-carboxyfluorescein) channel (excitation at
470 nm; detection at 510 nm), and first derivative analysis for themeasurement
analysis was conducted using Rotor-Gene 6 software.
Chemical Compounds and Syntheses
See full methods in Supplemental Experimental Procedures for the detailed
synthesis.
Animals, Infections, Cells, and Coculture Assays
Protocol approval and ethical clearance for animal handling was obtained from
the Landesamt fu¨r Natur Umwelt und Verbraucherschutz Nordrhein Westfalen
in Recklinghausen, Germany (AZ 8.87-50.10.35.08.024). German and Euro-
pean Union guidelines to minimize animal suffering were followed. Av-infected
Mongolian gerbils were kindly provided by Dr. R. Lucius (Humboldt-Universita¨t
zu Berlin, Berlin, Germany).
The Ls cycle was maintained at the University Hospital of Bonn (Bonn,
Germany) as previously described (Al-Qaoud et al., 1997). For natural infection
with Ls, anesthetized gerbils were exposed to tropical dust mites (Ornithonys-
sus bacoti) infected with Ls. Patently infected animals were euthanized after 3–
9 months postinfection, and adult Ls worms were isolated from the pleural
cavity. Av were isolated from the subcutaneous tissue of gerbils 6–12 months
after infection. Isolated adult female worms of Ls or Av were washed and
placed on a confluent lawn of LLC-MK2 cells (a kind gift of S. Townson, Lon-
don School of Hygiene and Tropical Medicine) in six-well plates (six worms per
group) and kept at 37C, 5% CO2. After 24 hr, worms were exposed to the
drugs or 1% DMSO control in 3 ml medium for 14–17 days. Medium was
exchanged every 2 days. Please refer to Supplemental Experimental Proce-
dures for a description of the motility scores and worm viability measurements
by MTT assay adapted from a study initially describing the coculture system
for male adults of another filarial species (Townson et al., 2006).
Statistics and Data Analyses
All data and statistics were analyzed using Prism 5.0 (GraphPad Software).
Results of enzymatic assays are given as the mean ± SEM. Curves were fitted
using the ‘‘loginhibitor versus normalized response  variable slope’’ nonlinear
regression algorithm. Hill-slope values were allowed to adopt values different
from 1 due to the possibility of different cooperative effects on ALAD
oligomers. Predicted Hill-slope values ranged from 0.45 to 0.81. For
type-of-inhibition experiments, primary data were fitted using the mixed
model inhibition algorithm and linear Eadie-Hofstee representations were
generated. Statistical analyses were conducted using the nonparametric
two-tailed Mann-Whitney U test for significance testing with a significance
level of a = 0.05.–187, February 21, 2013 ª2013 Elsevier Ltd All rights reserved 185
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Supplemental Information includes four figures, one table, five movies, and
Supplemental Experimental Procedures and can be found with this article
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